Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Fowler

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|April 3, 2019
Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and OutcomesTherese Andraos, Zeina Ayoub, Loretta Nastoupil, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 14, 2015
Effect of hepatitis C virus infection in patients with cancer: addressing a neglected populationHarrys A Torres, Parag Mahale, Boris Blechacz, et al.
Leukemia & Lymphoma|January 5, 2024
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphomaMichael Dickinson, Joaquin Martinez-Lopez, Etienne Jousseaume, et al.
Leukemia & Lymphoma|September 14, 2020
Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphomaFelipe Samaniego, Peter McLaughlin, Sattva S Neelapu, et al.
Leukemia & Lymphoma|July 25, 2013
Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphomaQasiem J Nasser, Margaret L Pfeiffer, Jorge Romaguera, et al.
British Journal of Haematology|July 28, 2015
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphomaYasuhiro Oki, Michelle Fanale, Jorge Romaguera, et al.
Cancer Causes & Control : CCC|March 20, 2019
Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national dataDima Dandachi, Quinn T Ostrom, Insun Chong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2026
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT TrialJohn P Leonard, Marek Trněný, Huilai Zhang, et al.
International Journal of Hematology|November 20, 2022
Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trialNoriko Fukuhara, Koji Kato, Hideki Goto, et al.
Human Genetics|December 2, 2025
MutAnt: mutation annotation tool predicts deleteriousness of missense mutations and improves mutation calling from transcriptomicsAleksandr Sarachakov, Anastasiya Yudina, Viktor Svekolkin, et al.
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Clinical Lymphoma, Myeloma & Leukemia|April 3, 2019
Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and OutcomesTherese Andraos, Zeina Ayoub, Loretta Nastoupil, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 14, 2015
Effect of hepatitis C virus infection in patients with cancer: addressing a neglected populationHarrys A Torres, Parag Mahale, Boris Blechacz, et al.
Leukemia & Lymphoma|January 5, 2024
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphomaMichael Dickinson, Joaquin Martinez-Lopez, Etienne Jousseaume, et al.
Leukemia & Lymphoma|September 14, 2020
Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphomaFelipe Samaniego, Peter McLaughlin, Sattva S Neelapu, et al.
Leukemia & Lymphoma|July 25, 2013
Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphomaQasiem J Nasser, Margaret L Pfeiffer, Jorge Romaguera, et al.
British Journal of Haematology|July 28, 2015
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphomaYasuhiro Oki, Michelle Fanale, Jorge Romaguera, et al.
Cancer Causes & Control : CCC|March 20, 2019
Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national dataDima Dandachi, Quinn T Ostrom, Insun Chong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2026
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT TrialJohn P Leonard, Marek Trněný, Huilai Zhang, et al.
International Journal of Hematology|November 20, 2022
Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trialNoriko Fukuhara, Koji Kato, Hideki Goto, et al.
Human Genetics|December 2, 2025
MutAnt: mutation annotation tool predicts deleteriousness of missense mutations and improves mutation calling from transcriptomicsAleksandr Sarachakov, Anastasiya Yudina, Viktor Svekolkin, et al.
Pageof 9